Streetbeat News

Products Services

ENVB

Enveric Biosciences has received a Notice of Allowance from the USPTO for its EVM301 series of drug candidates, which are designed to address various central nervous system disorders.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:03 pm

NEXI

NexImmune presented initial data from its NEXI-001 Phase 1 trial for relapsed/refractory post allo-HSCT AML at the 2023 ASCO Meeting. The trial showed a favorable safety profile and robust immune response, with one patient achieving no evidence of disease 7 months post-infusion.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:02 pm

IMRX

Immuneering has completed dose escalation in its IMM-1-104 Phase 1 clinical trial for RAS-mutant, advanced solid tumors. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of the drug.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:02 pm

HZNP

Horizon Therapeutics announced that data from its TEPEZZA Phase 4 clinical trial in patients with chronic/low CAS thyroid eye disease will be presented at the Endocrine Society Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:02 pm

MASI

Masimo Corporation (MASI) has received FDA 510(k) clearance for its Radius VSM, a wearable vital signs monitor. This clearance allows the company to market and sell the device in the United States.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:01 pm

TSHA

Taysha Gene Therapies has announced the first patient dosed with TSHA-102 in the REVEAL Phase 1/2 trial, a randomized study evaluating the safety and preliminary efficacy of TSHA-102 in adults with Rett syndrome.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:01 pm

JNJ

Johnson & Johnson's Abiomed has recalled specific Impella 5.5 with SmartAssist devices due to purge fluid leaks that can cause pump stop and loss of support. The company has reported 179 complaints, three injuries, and no deaths related to the recall.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:00 pm

EVAX

Evaxion Biotech's melanoma trial met its primary endpoints, leading to a surge in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:49 am

BLPH

Bellerophon's Phase 3 REBUILD trial failed to meet its primary endpoint, causing the company's shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:48 am

ILMN

Grail Inc, a subsidiary of Illumina Inc (NASDAQ:ILMN), mistakenly sent form letters to 400 patients suggesting they may have developed cancer due to a software configuration error. The incident has led to MassMutual pausing its pilot and Principal reviewing its relationship with Grail.

Portfolio Pulse from Vandana Singh

June 05, 2023 | 11:47 am